A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Most melanomas have BRAF(V600) mutations, activating the MAPK pathway.
• MAPK pathway inhibitors benefit BRAF(V600)-mutant melanoma patients, but 10-20% show no response.
• The mechanisms behind intrinsic resistance to these inhibitors are not fully understood.

Purpose of the Study:

• To investigate the distinct transcriptional profiles of drug-sensitive and intrinsically resistant BRAF(V600)-mutant melanomas.
• To identify molecular factors contributing to treatment failure in a subset of melanoma patients.

Main Methods:

• Comparative transcriptional profiling of drug-sensitive and resistant melanoma cell lines and patient biopsies.
• Analysis of MITF (melanocytic lineage transcription factor) and NF-κB signaling pathways.
• In vitro experiments assessing drug response in melanomas with distinct transcriptional states.

Main Results:

• BRAF(V600)-mutant melanomas exhibit distinct transcriptional profiles based on drug sensitivity.
• Drug-sensitive melanomas show high MITF expression, while resistant ones display low MITF and high NF-κB signaling and AXL expression.
• NF-κB activation antagonizes MITF, induces resistance markers, and confers resistance to MAPK pathway inhibitors (RAF, MEK, ERK).

Conclusions:

• A subset of BRAF(V600)-mutant melanomas exhibits intrinsic resistance to MAPK pathway inhibitors.
• Distinct transcriptional cell states, characterized by MITF or NF-κB activity, are linked to this intrinsic resistance.
• Understanding these cell states may help predict and overcome treatment failure in melanoma.